IAG’s Precision Medicine Approach in #Brain #Cancer is Selected for #ESMO Highlights & as an Oral Presentation, 19-23 Oct 2018 in Munich, Germany
Application of advanced imaging to support a novel precision medicine methodology in brain cancer will be presented at the upcoming ESMO meeting by Dr. Diana Roettger, the Head of Scientific and Medical Affairs. The presentation is also selected for ESMO Highlights.
This collaborative scientific work is focused on the application of advanced imaging techniques and artificial intelligence (#AI) for the characterization of brain cancer and targeted drug development.
Meet our team at the European Society for Medical Oncology (ESMO) held from 19 – 23 Oct 2018 in Munich, Germany.
Oral Presentation: Radiological phenotyping of IDH Mutation Status in Gliomas using Dynamic Susceptibility Contrast Perfusion-Weighted MRI. 19 October 2018, 16:00 – 17:30, Hall B3 – Room 20, Abstract No: 375O
IAG’s Oncology R&D team in collaboration with the colleagues from the University College London, Clinical Medical College of Jinan University, Shenzhen, China and researchers from Canada will also be presenting 2 posters, discussing the techniques for differentiation of #pseudoprogression from true progression in neuro-oncology and immune-oncology drug development.
Poster Discussion: Can Diffusion Tensor MR Imaging Identify Glioma IDH Mutation Status?
Poster display session: Breast cancer – early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours – prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care: 22.10.2018, 12:45 – 13:45, Hall A3 – Poster Area Networking Hub, Presentation Number: 396P, Poster No.: 2638, Sotirios Bisdas, Jialin Yuan, Laura Mancini, Diana Roettger
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: email@example.com
Follow the Company: Linkedin
ESMO is the leading European professional organisation for medical oncology. Comprising 18,000 oncology professionals from over 150 countries, we are the society of reference for oncology education and information. The meeting is a multi-professional platform for oncology education and exchange, and for immense international visibility for scientific research, this year the Congress also features a dedicated nursing track through a collaboration with the European Oncology Nursing Society (EONS).